Drug Profile
Ulenistamab - Prestige BioPharma
Alternative Names: Anti-PAUF antibody - Prestige Biopharma; PBP-1510Latest Information Update: 23 Mar 2023
Price :
$50
*
At a glance
- Originator Prestige BioPharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action PAUF protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pancreatic cancer
- Phase I/II Ovarian cancer
Most Recent Events
- 22 Mar 2023 Ulenistamab receives Fast Track designation for Pancreatic cancer [IV,Infusion] (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA
- 28 Feb 2023 Prestige Biopharma Limited files for patent protection for ulenistamab in 24 countries
- 28 Feb 2023 Prestige Biopharma Limited has patent protection for ulenistamab in USA, Korea and Singapore